Hepion Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
399 THORNALL STREET, EDISON, NJ, 08837
Mailing Address
399 THORNALL STREET, EDISON, NJ, 08837
Phone
732-902-4000
Fiscal Year End
1231
EIN
462783806
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 8-K Current report of material events | March 18, 2026 | View on SEC |
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 8-K Current report of material events | January 15, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Focus on research and development (R&D) of novel drug candidates, advancing new treatments through its development pipeline.
- Strategic Merger Agreement in January 2025 and a deal with NewDay Diagnostics LLC in May 2025, indicating potential consolidation or expansion.
Material Events
8-K
Leadership Change
March 18, 2026
High Impact
- Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on liver diseases like NASH.
- Its lead drug candidate, CRV-431, is in development for NASH.
8-K
Acquisition
March 3, 2026
High Impact
- Strategic diversification into liver health diagnostics, complementing existing therapeutic pipeline.
- Acquisition of a novel diagnostic tool for early detection of hepatocellular carcinoma (HCC), addressing a critical unmet need.
8-K
Leadership Change
January 15, 2026
High Impact
- Hepion Pharmaceuticals appointed Dr. Kaouthar Lbiati as new CEO to drive strategic growth.
- Dr. Lbiati brings over 20 years of experience in drug development, clinical operations, and strategic leadership, especially in liver disease and oncology.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.